Number of inclusion | Age at BC diagnosis | BC characteristics | Age at LM diagnosis | Clinical symptoms | Biochemical CSF analysis | Cytological CSF analysis | Neuraxis MRI |
---|---|---|---|---|---|---|---|
03 | 56 | Undifferenciated carcinoma, HPG 3, ER-, PR -, HER2- | 60 | Cognitive disorders | Proteinorachia: 0.24 g/l | Presence of malignant cells | LM involvement |
Glycorachia: 2.7 | Brain metastases | ||||||
Chlorurorachia: 118 | |||||||
05 | 61 | ILC, HPG 2, ER+, PR+, HER2- | 61 | Dizziness | Proteinorachia: 2.19 g/l | Presence of malignant cells | LM involvement |
Glycorachia: 1.7 | No brain metastases | ||||||
Chlorurorachia: 124 | |||||||
06 | 53 | Adenocarcinoma, HPG 2, ER+, PR+, HER2 - | 74 | None | Proteinorachia: 0.48 g/l | Presence of malignant cells | LM involvement |
Glycorachia: 3.5 | No brain metastases | ||||||
Chlorurorachia: 123 | |||||||
09 | 42 | Adenocarcinoma, HPG 2, ER+, PR +, HER2 - | 60 | Dizziness, deafness | Proteinorachia: 1.49 g/l | Presence of malignant cells | LM involvement |
Glycorachia: 2.7 | No brain metastases | ||||||
Chlorurorachia: 116 | |||||||
10 | 47 | IDC, HPG 2, ER+, PR+, HER2- | 59 | Visual disorders | Proteinorachia: 0.51 g/l | Presence of malignant cells | LM involvement |
Glycorachia: 4.0 | Brain metastases | ||||||
Chlorurorachia: 120 | |||||||
11 | 41 | ICL, HPG 3, ER+, PR -, HER2 + | 45 | Cauda equine syndrome | Proteinorachia: 7.08 g/l | Presence of malignant cells | LM involvement |
Glycorachia: 2 | Brain metastases | ||||||
Chlorurorachia: 113 | |||||||
12 | 44 | IDC, HPG 2, ER+, PR+, HER2 + | 57 | None | Proteinorachia: 0.28 g/l | Presence of malignant cells | LM involvement |
Glycorachia: 4.9 | Brain metastases | ||||||
Chlorurorachia: 120 | |||||||
13 | 45 | Undifferenciated carcinoma, HPG 3, ER+, PR+, HER2 - | 50 | Cauda equina syndrome | Proteinorachia: 5.80 g/l | Presence of malignant cells | LM involvement |
Glycorachia: 3.6 | Brain metastases | ||||||
Chlorurorachia: 111 |